Search
Giloralimab
go.drugbank.com/drugs/DB18862InvestigationalWith IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis). … Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination
SPC2968
go.drugbank.com/drugs/DB06351InvestigationalIt was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult
Budigalimab
go.drugbank.com/drugs/DB16668InvestigationalWith IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis). … Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination
Androstenediol
go.drugbank.com/drugs/DB01524ExperimentalIllicitto a 3-keto group (3-hydroxysteroid dehydrogenases). … Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group
SRP 299
go.drugbank.com/drugs/DB05440ExperimentalA specific subset of serotonergic neurons in the interfascicular part of the dorsal raphe nucleus (DRI) is believed to be involved, based on studies with mice. … SRP 299 is a preparation of killed Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and in treating eczema, itching and inflammation.
Tipifarnib
go.drugbank.com/drugs/DB04960InvestigationalIt belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
COVID-19 convalescent plasma
go.drugbank.com/drugs/DB15692InvestigationalCOVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2. … [L14333] Although there are no formal clinical trial results for the safety or efficacy of COVID-19 convalescent plasma, early results from 5000 patients under the FDA expanded access program suggest
TRX1
go.drugbank.com/drugs/DB05863ExperimentalTRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells.
Elesclomol
go.drugbank.com/drugs/DB05719InvestigationalIn preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal
CYP-001
go.drugbank.com/drugs/DB15739InvestigationalThese cells are used to treat chronic allergic airway disease and fibrosis, among other pathologies. … These cells are then able to differentiate into bone, cartilage, and adipose tissue. The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media.